Advanced Solid Tumor
765
263
335
167
Key Insights
Highlights
Success Rate
63% trial completion
Published Results
46 trials with published results (6%)
Research Maturity
167 completed trials (22% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
12.5%
96 terminated out of 765 trials
63.5%
-23.0% vs benchmark
0%
2 trials in Phase 3/4
28%
46 of 167 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 167 completed trials
Clinical Trials (765)
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
A Study of IDP-001 in Advanced or Metastatic Solid Tumors
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies
Neoadjuvant Short-Course Radiotherapy Followed by CAPOX Plus PD-1 Antibody and IL-2 in Locally Advanced Rectal Cancer (PRIDE01)
Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors
SLV-154 Treatment of Advanced Cancers
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors